Govoptes

HRES 1285 · Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Referred to the House Committee on Energy and Commerce.

Introduced
May 14, 2026
Latest action
May 14, 2026
Sponsor
Rep. Diana DeGette [D-CO-1]
Policy area
Unassigned
Cosponsors
42

Recent actions

  1. May 14, 2026 Referred to the House Committee on Energy and Commerce.
  2. May 14, 2026 Submitted in House

Votes

No recorded votes are available for this bill.

Related pages